Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Travere ...

Travere Therapeutics (NASDAQ:TVTX) highlighted record demand for FILSPARI in IgA nephropathy (IgAN), provided an update on the U.S. Food and Drug Administration’s review timeline for a potential focal ...

Learn more about whether IDEAYA Biosciences, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ ...

Analysts anticipate Travere Therapeutics to report an earnings per share (EPS) of $0.24. The market awaits Travere ...

FILSPARI generated $103.3 million in U.S. net product sales for Q4 and $322 million for the full year. Thiola and Thiola EC contributed $23.3 million in U.S. net product sales during Q4 and $88.5 ...

The drug developer posted revenue of $129.7 million in the period, which did not meet Street forecasts. Six analysts surveyed ...

Travere Therapeutics Inc reports fourth-quarter earnings Thursday after market close, with investors focused on the rare ...

Travere Therapeutics (NASDAQ: TVTX) reported its Q4 earnings results on Thursday, February 19, 2026 at 04:01 PM. Here's what investors need to know about the announcement. Travere Therapeutics beat ...

For the quarter ended December 2025, Travere Therapeutics (TVTX) reported revenue of $129.69 million, up 73.4% over the same period last year. EPS came in at $0.03, compared to -$0.73 in the year-ago ...

If you are wondering whether Travere Therapeutics at around US$27.82 still offers value, you are not alone, many investors are asking the same question as the stock has been on the radar of biotech ...

Travere Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.